Skip to main content
Top
Published in: Clinical Rheumatology 6/2009

01-06-2009 | Original Article

Interstitial lung disease in polymyositis and dermatomyositis

Authors: I-Jung Chen, Yeong-Jian Jan Wu, Cho-Wei Lin, Kang-Wei Fan, Shue-Fen Luo, Huei-Huang Ho, Lieh-Bang Liou, Wen-Pin Tsai, Ji-Yih Chen, Chung-Han Yang, Chang-Fu Kuo, Kuang-Hui Yu

Published in: Clinical Rheumatology | Issue 6/2009

Login to get access

Abstract

The aim of the study was to estimate the prevalence, characteristics, and prognostic factors of interstitial lung disease (ILD) in patients with polymyositis (PM) and dermatomyositis (DM). The medical records of 151 PM/DM patients treated at Chang Gung Memorial Hospital between January, 2000 and June, 2007 were retrospectively reviewed. Thirty of 151 (19.9%) PM/DM patients had developed ILD. Older age at PM/DM onset, anti-Jo-1 antibody, and arthritis/arthralgia were associated with the presence of ILD (p = 0.004, p = 0.008, and p = 0.026, respectively). Anti-Jo-1 was initially excluded from the multivariate analysis because only 80 patients underwent the test. An older age at onset above 45 years (odds ratio 3.28, 95% confidence interval (CI) 1.15–9.34, p = 0.026) and arthritis/arthralgia at onset (odds ratio (OR) 2.57, 95% CI 1.09–6.08, p = 0.032) were the two independent risk factors for developing ILD. If anti-Jo-1 was included in the multivariate analysis (n = 80), then an older age at onset above 45 years (OR 7.30, 95% CI 1.70–31.40, p = 0.008) and anti-Jo-1 positive (OR 7.89, 95% CI 1.18–52.87, p = 0.033) were associated with ILD, while arthritis/arthralgia was no longer significant (OR 2.64, 95% CI 0.70–10.01, p = 0.153). Of the 30 ILD patients, 16 (53.3%) died. The survival time was significantly shorter in ILD patients than in patients without ILD (p < 0.001). Poor survival in ILD patients was associated with male gender (p = 0.039), a Hamman–Rich-like presentation (p = 0.039), and a clinical diagnosis of acute interstitial pneumonia (p = 0.007).
Literature
1.
go back to reference Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin North Am 48:1031–1042PubMed Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin North Am 48:1031–1042PubMed
2.
go back to reference Frazier AR, Miller RD (1974) Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 65:403–407PubMedCrossRef Frazier AR, Miller RD (1974) Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 65:403–407PubMedCrossRef
3.
go back to reference Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706PubMedCrossRef Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706PubMedCrossRef
4.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMed
5.
go back to reference Euwer RL, Sontheimer RD (1993) Amyopathic dermatomyositis: a review. J Invest Dermatol 100:124S–127SPubMedCrossRef Euwer RL, Sontheimer RD (1993) Amyopathic dermatomyositis: a review. J Invest Dermatol 100:124S–127SPubMedCrossRef
6.
go back to reference Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef
7.
go back to reference Ansell BM (1991) Juvenile dermatomyositis. Rheum Dis Clin North Am 17:931–942PubMed Ansell BM (1991) Juvenile dermatomyositis. Rheum Dis Clin North Am 17:931–942PubMed
8.
go back to reference Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508PubMedCrossRef Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508PubMedCrossRef
9.
go back to reference Tazelaar HD, Viggiano RW, Pickersgill J et al (1990) Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 141:727–733PubMed Tazelaar HD, Viggiano RW, Pickersgill J et al (1990) Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 141:727–733PubMed
10.
go back to reference Marie I, Hachulla E, Chérin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622PubMedCrossRef Marie I, Hachulla E, Chérin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622PubMedCrossRef
11.
go back to reference American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) Am J Respir Crit Care Med 165:277–304 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) Am J Respir Crit Care Med 165:277–304
12.
go back to reference Yu KH, Yang CH, Wu YK et al (2006) Diffuse alveolar damage as the initial presentation of dermatomyositis and successfully treated with intravenous immunoglobulin and steroids: a case report. J Musculoskel Pain 14:45–50CrossRef Yu KH, Yang CH, Wu YK et al (2006) Diffuse alveolar damage as the initial presentation of dermatomyositis and successfully treated with intravenous immunoglobulin and steroids: a case report. J Musculoskel Pain 14:45–50CrossRef
13.
go back to reference MIills ES, Mathews WH (1956) Interstitial pneumonitis in dermatomyositis. J Am Med Assoc 160:1467–1470 MIills ES, Mathews WH (1956) Interstitial pneumonitis in dermatomyositis. J Am Med Assoc 160:1467–1470
14.
go back to reference Fujisawa T, Suda T, Nakamura Y et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed Fujisawa T, Suda T, Nakamura Y et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed
15.
go back to reference Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomypsitis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654PubMedCrossRef Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomypsitis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654PubMedCrossRef
16.
go back to reference Schnabel A, Reuter M, Biederer J et al (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthitis Rheum 32:273–284CrossRef Schnabel A, Reuter M, Biederer J et al (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthitis Rheum 32:273–284CrossRef
17.
go back to reference Fathi M, Dastmalchi M, Rasmussen E et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63:297–301PubMedCrossRef Fathi M, Dastmalchi M, Rasmussen E et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63:297–301PubMedCrossRef
18.
go back to reference Grau JM, Miró O, Pedrol E et al (1996) Interstitial lung disease related to dermatomyositis: comparable study with patients without lung involvement. J Rheumatol 23:1921–1926PubMed Grau JM, Miró O, Pedrol E et al (1996) Interstitial lung disease related to dermatomyositis: comparable study with patients without lung involvement. J Rheumatol 23:1921–1926PubMed
19.
go back to reference Kang EH, Lee EB, Shin KC et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 44:1282–1286PubMedCrossRef Kang EH, Lee EB, Shin KC et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 44:1282–1286PubMedCrossRef
20.
go back to reference Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 83:35–42PubMedCrossRef Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 83:35–42PubMedCrossRef
21.
go back to reference Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14:534–542PubMedCrossRef Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14:534–542PubMedCrossRef
22.
go back to reference Chen YJ, Wu CY, Shen JL (2007) Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 87:33–38PubMedCrossRef Chen YJ, Wu CY, Shen JL (2007) Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 87:33–38PubMedCrossRef
23.
go back to reference Stone KB, Oddis CV, Fertig N et al (2007) Anti-Jo-1 antibody levels correlated with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56:3125–3131PubMedCrossRef Stone KB, Oddis CV, Fertig N et al (2007) Anti-Jo-1 antibody levels correlated with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56:3125–3131PubMedCrossRef
24.
go back to reference Mielnik P, Wiesik-Szewczyk E, Olesinska M et al (2006) Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 39:243–247PubMedCrossRef Mielnik P, Wiesik-Szewczyk E, Olesinska M et al (2006) Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 39:243–247PubMedCrossRef
25.
go back to reference Suda T, Fujisawa T, Enomoto N et al (2006) Interstitial lung disease associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012PubMedCrossRef Suda T, Fujisawa T, Enomoto N et al (2006) Interstitial lung disease associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012PubMedCrossRef
26.
go back to reference Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185PubMed Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185PubMed
27.
go back to reference Tansey D, Wells AU, Colby TV et al (2004) Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44:585–596PubMedCrossRef Tansey D, Wells AU, Colby TV et al (2004) Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44:585–596PubMedCrossRef
28.
go back to reference Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–250PubMedCrossRef Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–250PubMedCrossRef
29.
go back to reference Won Huh J, Soon Kim D, Keun Lee C et al (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761–1769PubMedCrossRef Won Huh J, Soon Kim D, Keun Lee C et al (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761–1769PubMedCrossRef
30.
go back to reference Ito M, Kaise S, Suzuki S et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18:462–467PubMedCrossRef Ito M, Kaise S, Suzuki S et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18:462–467PubMedCrossRef
31.
go back to reference Oddis CV (2000) Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12:492–497PubMedCrossRef Oddis CV (2000) Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12:492–497PubMedCrossRef
32.
go back to reference Nawata Y, Kurasawa K, Takabayashi K et al (1999) Corticosteroid resistant interstitial pneumonitis in polymyositis/dermatomyositis: prediction and treatment with cyclosporine. J Rheumatol 26:1527–1533PubMed Nawata Y, Kurasawa K, Takabayashi K et al (1999) Corticosteroid resistant interstitial pneumonitis in polymyositis/dermatomyositis: prediction and treatment with cyclosporine. J Rheumatol 26:1527–1533PubMed
33.
go back to reference Yoshida T, Koga H, Saitoh F et al (1999) Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 38:733–738PubMedCrossRef Yoshida T, Koga H, Saitoh F et al (1999) Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 38:733–738PubMedCrossRef
34.
go back to reference Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRef Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRef
Metadata
Title
Interstitial lung disease in polymyositis and dermatomyositis
Authors
I-Jung Chen
Yeong-Jian Jan Wu
Cho-Wei Lin
Kang-Wei Fan
Shue-Fen Luo
Huei-Huang Ho
Lieh-Bang Liou
Wen-Pin Tsai
Ji-Yih Chen
Chung-Han Yang
Chang-Fu Kuo
Kuang-Hui Yu
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1110-6

Other articles of this Issue 6/2009

Clinical Rheumatology 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.